By Nick Johnson (Apyx) In 2023 Shareholder News, J-Plasma, RenuvionPosted November 28, 2023APYX MEDICAL CORPORATION APPOINTS MATTHEW HILL AS CHIEF FINANCIAL OFFICER READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, J-Plasma, RenuvionPosted November 9, 2023APYX MEDICAL CORPORATION ANNOUNCES NEW DEBT FACILITY WITH PERCEPTIVE ADVISORS READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, J-Plasma, RenuvionPosted November 9, 2023APYX MEDICAL CORPORATION REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND UPDATES FULL YEAR 2023 FINANCIAL OUTLOOK READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted November 7, 2023APYX MEDICAL CORPORATION TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN NOVEMBER READ MORE
By apyxmedical In 2023 Shareholder News, J-Plasma, RenuvionPosted October 2, 2023APYX MEDICAL CORPORATION TO RELEASE THIRD QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON NOVEMBER 9, 2023 READ MORE
By apyxmedical In 2023 Shareholder News, J-Plasma, RenuvionPosted August 10, 2023APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND REAFFIRMS FULL YEAR 2023 FINANCIAL OUTLOOK READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, J-Plasma, RenuvionPosted June 29, 2023APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON AUGUST 10, 2023 READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted June 14, 2023APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) CLEARANCE FOR THE RENUVION MICRO HANDPIECE READ MORE
By apyxmedical In 2023 Shareholder News, J-Plasma, RenuvionPosted May 11, 2023APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES FULL YEAR 2023 FINANCIAL OUTLOOK READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted May 2, 2023RENUVION RECEIVES FDA CLEARANCE FOR SPECIFIC USE AFTER LIPOSUCTION READ MORE
